Atai Life Sciences (ATAI) Stock Price, News & Analysis

Company Overview

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Key Stats

• Today's Range: $1.38 to $1.45
• 50-Day Range: $1.21 to $1.61
• 52-Week Range: $1.03 to $2.57
• Volume: 1.08 million shs
• Average Volume: 1.52 million shs
• Market Capitalization: $277.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.50
• Consensus Rating: Buy

Atai Life Sciences Stock Analysis - MarketRank™

Atai Life Sciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 611th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Atai Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atai Life Sciences is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atai Life Sciences is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atai Life Sciences has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.91% of the float of Atai Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Atai Life Sciences has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atai Life Sciences does not currently pay a dividend.

Dividend Growth

Atai Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.91% of the float of Atai Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Atai Life Sciences has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Atai Life Sciences this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

5 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Atai Life Sciences insiders have bought 20,428.49% more of their company's stock than they have sold. Specifically, they have bought $22,755,008.00 in company stock and sold $110,846.00 in company stock.

Percentage Held by Insiders

31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 28.41% of the stock of Atai Life Sciences is held by institutions.

ATAI Stock Analysis - Frequently Asked Questions

How have ATAI shares performed this year?

Atai Life Sciences' stock was trading at $1.33 at the start of the year. Since then, ATAI shares have increased by 4.5% and is now trading at $1.39.
View the best growth stocks for 2025 here.

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings data on Monday, March, 17th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.10. The business had revenue of ($0.01) million for the quarter, compared to analysts' expectations of $0.30 million.

When did Atai Life Sciences IPO?

Atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' top institutional shareholders include BIT Capital GmbH (0.22%), Capital Advisors Inc. OK (0.04%), Kingswood Wealth Advisors LLC (0.04%) and Regent Peak Wealth Advisors LLC (0.01%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar and Srinivas Rao.
View institutional ownership trends.

How do I buy shares of Atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATAI
• CIK: 1420529
• Web: www.atai.net.cn
• Phone: 49-89-2153-9035
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.50
• High Stock Price Target: $11.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +655.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,220,000.00
• Net Margins: N/A
• Pretax Margin: -38,531.72%
• Return on Equity: -65.75%
• Return on Assets: -52.71%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: $308,000.00
• Price / Sales: 901.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.47 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 199,795,000
• Free Float: 115,448,000
• Market Cap: $277.72 million
• Optionable: Optionable
• Beta: 1.22